Get started
Author

Lorenzo Cani

Observed name: L. Cani
ORCID: 0009-0004-0945-0144
Observed ORCID: 0009-0004-0945-0144
OpenAlex ID: A5048825258
Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting
2022 · Francesca Bonello, Lorenzo Cani, et al. · Frontiers in Oncology · 22
PDF
New Strategies for the Treatment of Older Myeloma Patients
2023 · Alessandra Larocca, Lorenzo Cani, et al. · Cancers · 13
PDF
Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
2024 · Lorenzo Cani, Sara A. Scott, et al. · Blood · 9
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
2026 · Lorenzo Cani, Richa Parikh, et al. · Clinical Lymphoma Myeloma & Leukemia · 8
PDF
Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians
2024 · Tommaso Lupia, Lorenzo Cani, et al. · Clinical Lymphoma Myeloma & Leukemia · 8
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
2025 · Lorenzo Cani, Sara A. Scott, et al. · Haematologica · 7
PDF
BCL2 inhibition for multiple myeloma and AL amyloidosis
2025 · Lorenzo Cani, Vikas A. Gupta, et al. · British Journal of Haematology · 5
PDF
A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis
2024 · Claudia Bellofiore, Pietro Benvenuti, et al. · Hematological Oncology · 4
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy
2025 · Lorenzo Cani, Maria Teresa Petrucci, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
2022 · Giuseppe Bertuglia, Lorenzo Cani, et al. · International Journal of Molecular Sciences · 3
PDF
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide
2025 · I. Rizzello, I. Sacchetti, et al. · Clinical and Experimental Medicine · 2
PDF
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
2025 · Sara Bringhen, Lorenzo Cani, et al. · The Lancet Haematology · 2
P-416 A Multicenter Observational Retrospective Study of Second-Line Treatment With Daratumumab–Bortezomib–Dexamethasone (DaraVd) in Multiple Myeloma (MM) Patients Refractory to Lenalidomide
2024 · Ilaria Rizzello, Ilaria Sacchetti, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial
2025 · Mattia D'Agostino, Sara Bringhen, et al. · Blood · 1
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
2025 · Sara Bringhen, Lorenzo Cani, et al. · Haematologica · 1
PDF
Infection Prevention and Management in Patients With Multiple Myeloma Treated With Bispecific Antibodies: A Case-Based Approach for Routine Clinical Practice
2026 · Lorenzo Cani, Michele Puppi, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-095 Clinical Implications of Discordant Frailty Assessment in Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Results from the Randomized Phase IV REAL MM Trial
2026 · Lorenzo Cani, Mattia D'Agostino, et al. · Clinical Lymphoma Myeloma & Leukemia
Beyond Immunomodulatory Drugs: Next-Generation Cereblon Modulators in Multiple Myeloma
2026 · Lorenzo Cani, Roberto Mina, et al. · The Cancer Journal
Demodex ‐associated dermatoses after allogeneic HSCT : A retrospective multicentre study
2026 · Jessica Gill, María Martínez‐Fernández, et al. · Journal of the European Academy of Dermatology and Venereology
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management
2026 · Roberto Mina, Evangelos Terpos, et al. · Clinical Lymphoma Myeloma & Leukemia
Author response for "A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis"
2024 · Claudia Bellofiore, Pietro Benvenuti, et al.
Works count: 21
Citation count: 90
H-index: 6
I10-index: 2
Year
Topic
Type